NYSE:VNRX opened at $2.61 on Thursday. The stock has a market capitalization of $140.39 million, a price-to-earnings ratio of -5.02 and a beta of 1.65. The company has a fifty day simple moving average of $2.74. The company has a quick ratio of 1.48, a current ratio of 1.48 and a debt-to-equity ratio of 0.23. VolitionRx has a 12 month low of $2.08 and a 12 month high of $4.14.
VolitionRx (NYSE:VNRX – Get Rating) last posted its earnings results on Wednesday, March 30th. The company reported ($0.15) EPS for the quarter. The business had revenue of $0.01 million during the quarter, compared to analysts’ expectations of $0.03 million. VolitionRx had a negative net margin of 15,827.93% and a negative return on equity of 148.44%. On average, equities research analysts anticipate that VolitionRx will post -0.54 EPS for the current fiscal year.
VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose a range of cancers and other diseases worldwide. It sells Nu.Q that detect cancer; Nu.Q Nets, monitoring the immune system; Nu.Q Vet cancer screening test for veterinary applications; Nu.Q Capture capturing and concentrating samples for more accurate diagnosis; and Nu.Q Discover, a solution to profiling nucleosomes.
- Get a free copy of the StockNews.com research report on VolitionRx (VNRX)
- Simply Good Foods Stock is Simply Looking Good Down Here
- Shoe Carnival’s Q1 Results Are No Joke, Shares Fall 15%
- Dynatrace: Fundamentals are Positive While Being Punished
- Analog Devices Is Ready To Scale New Highs Despite Tech Wreck
- Now’s The Time To Buy Disney (NYSE: DIS)
Receive News & Ratings for VolitionRx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VolitionRx and related companies with MarketBeat.com's FREE daily email newsletter.